Veracyte (VCYT) is initiating 2026 total revenue guidance of 10% to 13% growth, or $570 million to $582 million, with testing revenue guidance of 14% to 16% growth, or $559 million to $569 million, excluding the contribution from new tests. Further, 2026 adjusted EBITDA margin is expected to be 25%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT: